TRAIL is currently undergoing phase I/II clinical evaluation for a varietyof cancers, and it holds real promise as a therapeutic strategy owing to its selectivetargeting of cancer cells while sparing normal tissues (Abdulghani and El-Deiry, 2010; Amm et al., 2011). Here, TNFSF10 is linked to cancer.